{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-032870","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.867051+00:00","generated_at":"2026-05-17T00:37:55.315470+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Genprex announces European Patent Office intent to grant patent for Reqorsa with PD-1 antibodies","bullets":["European Patent Office communicated intent to grant patent for Reqorsa gene therapy combined with PD-1 antibodies for cancer.","Existing patents already granted in US, Japan, Mexico, Russia, Australia, Chile, China, and Singapore.","Reqorsa initially developed for lung cancer with approved drugs; shown complementary in preclinical studies.","Company believes Reqorsa's unique attributes may improve current therapies for lung and other cancers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-032870","json":"https://secwatch.observer/filing/0001437749-25-032870.json","markdown":"https://secwatch.observer/filing/0001437749-25-032870.md","text":"https://secwatch.observer/filing/0001437749-25-032870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/0001437749-25-032870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774925032870/gnpx20251024_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:37:55.315470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}